SCHAUMBURG, Ill.--(BUSINESS WIRE)--APP Pharmaceuticals, Inc. (Nasdaq: APPX), a leading provider of hospital-based injectable pharmaceutical products, today said that the U.S Food and Drug Administration (FDA) has approved APP’s manufacturing facility in Barceloneta, Puerto Rico for the manufacture of three product codes of Heparin Sodium Injection, USP.
